A novel clinically relevant graft-versus-leukemia model in humanized mice
Authors:
- 31 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 111 (2) , 427-437
Abstract
The prognosis for acute myeloid leukemia (AML) relapse post allogeneic hematopoietic stem cell transplantation (alloSCT) is dismal. Novel effective treatment is urgently needed. Clinical benefit of alloSCT greatly relies on the graft-versus-leukemia (GVL) effect. The mechanisms that mediate immune escape of leukemia (thus causing GVL failure) remain poorly understood. Studies of human GVL have been hindered by the lack of optimal clinically relevant models. Here, using our large, longitudinal clinical tissue bank that include AML cells and G-CSF mobilized donor hematopoietic stem cells (HSCs), we successfully established a novel GVL model in humanized mice. Donor HSCs were injected into immune-deficient NOD-Cg-PrkdcscidIL2rgtm1Wjl/SzJ (NSG) mice to build humanized mice. Immune reconstitution in these mice recapitulated some clinical scenario in the patient who received the corresponding HSCs. Allogeneic but HLA partially matched patient-derived AML cells were successfully engrafted in these humanized mice. Importantly, we observed a significantly reduced (yet incomplete elimination of) leukemia growth in humanized mice compared with that in control NSG mice, demonstrating a functional (but defective) GVL effect. Thus, for the first time, we established a novel humanized mouse model that can be used for studying human GVL responses against human AML cells in vivo. This novel clinically relevant model provides a valuable platform for investigating the mechanisms of human GVL and development of effective leukemia treatments.Keywords
This publication has 47 references indexed in Scilit:
- Graft versus Host Disease in the Bone Marrow, Liver and Thymus Humanized Mouse ModelPLOS ONE, 2012
- Advances in graft-versus-host disease biology and therapyNature Reviews Immunology, 2012
- Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor–, granulocyte-macrophage colony-stimulating factor–, and interleukin-3–expressing NOD-SCID IL2Rγnull humanized miceBlood, 2011
- PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cellsBlood, 2011
- Links between Progressive HIV-1 Infection of Humanized Mice and Viral NeuropathogenesisThe American Journal of Pathology, 2010
- Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγnullhumanized miceProceedings of the National Academy of Sciences, 2010
- Loss of Mismatched HLA in Leukemia after Stem-Cell TransplantationNew England Journal of Medicine, 2009
- A robust xenotransplantation model for acute myeloid leukemiaLeukemia, 2009
- Mouse Models of Bone Marrow TransplantationTransplantation and Cellular Therapy, 2008
- Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantationBlood, 2006